Results 41 to 50 of about 5,449 (190)

Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance

open access: yesNature Communications, 2023
The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a clinically-used sideromycin, that is utilized for the treatment of severe ...
Chenyuan Wang   +9 more
doaj   +1 more source

Carbapenem- and cefiderocol-resistant Enterobacterales in surface water in Kumasi, Ashanti Region, Ghana [PDF]

open access: yes
Background: MDR pathogens including ESBL- and/or carbapenemase-producing Enterobacterales (ESBL-PE and CPE) increasingly occur worldwide in the One Health context.
Eger, Elias   +9 more
core   +1 more source

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae

open access: yesMicrobiology Spectrum, 2023
Cefiderocol and aztreonam-avibactam (ATM-AVI) both had activity against carbapenem-resistant Gram-negative bacilli, including those that produce metallo-β-lactamases (MBLs).
Yu-Shan Huang   +3 more
doaj   +1 more source

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

open access: yesLife, 2023
Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-
Sara Domingues   +3 more
doaj   +1 more source

Rational Design of a Synthetic Galliphore for the Diagnostic Nuclear Imaging and Treatment of Bacterial Infections

open access: yesAngewandte Chemie International Edition, EarlyView.
KO‐NH2 is a synthetic metallophore that preferentially binds Ga3+ over Fe3+ and is recognized by bacterial transporters. Photocrosslinking identifies CirA and Fiu as key uptake proteins in E. coli. KO‐NH2 enables targeted imaging and treatment of E. coli soft tissue infections.
Phuong Nguyen Tran   +5 more
wiley   +1 more source

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol

open access: yesFrontiers in Pharmacology, 2021
Background: Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by ...
Yasaman Taheri   +7 more
doaj   +1 more source

Cefiderocol-associated brown chromaturia

open access: yesBMJ Case Reports, 2023
Cefiderocol is a novel siderophore cephalosporin antibiotic. In the present case report, a woman in her 70s presented with a 1-week history of altered mental status and progressive purulent discharge from a non-healing diabetic foot ulcer on her right heel. MRI of the right foot revealed chronic osteomyelitis of the calcaneum.
Michael Smith, Kap Sum Foong
openaire   +3 more sources

Development of cefiderocol resistance during treatment in Klebsiella pneumoniae

open access: yes, 2023
International audienceBackgroundCefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant Gram-negative bacteria. Mutations in siderophore receptors are described to confer multiple levels
Marchand, Sandrine   +4 more
core   +1 more source

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

open access: yesiLABMED, EarlyView.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa

open access: yesAntimicrobial Agents and Chemotherapy
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases.
Lucía González-Pinto   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy